Cytovant Sciences is a clinical-stage biopharmaceutical company dedicated to developing novel and innovative cellular therapeutics in Asia. Cytovant’s mission is to become Asia’s premier cell therapy company by discovering, developing, and commercializing new medicines that are uniquely suited to Asian patients.
Launched by ROIVANT SCIENCES in April 2019 to address Asia’s most pressing health concerns, our company is headquartered in Hong Kong with offices in Shanghai and Beijing, China. At Cytovant, we focus on research and development programs of cell therapy that have the potential to transform the treatment of diseases prevalent in Asia. While cell therapy is currently saturated by CAR-T approaches for hematologic oncology indications, we believe that TCR-T may better enable solid tumor targeting, a larger market opportunity than blood cancers. However, Asian populations have unique immunological characteristics and specific disease burdens, and these are not well addressed by the majority of TCR-T therapies in development.
To accelerate the delivery of important new cell therapies to Asian patients, we have entered into a multi-program license and collaboration agreement with Medigene AG, a German clinical-stage biotechnology company focusing on the development of T cell immunotherapies. Our most advanced R&D program, CVT-TCR-01, is a potential best-in-class NY-ESO-1-targeted TCR-T therapy for the treatment of multiple solid tumor types.